SAGE PRO

Home / Research / Clean Science and Technology Limited

SAGE PRO · ORIGINAL EQUITY RESEARCH

Clean Science and Technology Limited — Q2 FY27 Results Analysis

Revenue rose 22%

Published · Quarter Q2 FY27 · CLEAN

PeriodQ2 FY27
COMPANY-SPECIFIC GRAPHICAL SUMMARY

What the reported figures reveal

CHART 1

Group quarterly revenue

Q2 FY26₹245 crore
Q2 FY27₹299 crore
CHART 2

Group quarterly EBITDA

Q2 FY26₹87 crore
Q2 FY27₹92 crore
CHART 3

Group EBITDA margin

Q2 FY2636.4%
Q2 FY2731.2%
CHART 4

Group PAT

Q2 FY26₹55 crore
Q2 FY27₹56 crore
ORIGINAL RESEARCH INSIGHTS

Investment findings and watch points

RESEARCH INSIGHT

Revenue rose 22%

Group quarterly revenue changed from 245 ₹ crore (Q2 FY26) to 299 ₹ crore (Q2 FY27). Revenue rose 22%.

Watch: Disaggregate subsidiary sales

RESEARCH INSIGHT

EBITDA rose only 5%

Group quarterly EBITDA changed from 87 ₹ crore (Q2 FY26) to 92 ₹ crore (Q2 FY27). EBITDA rose only 5%.

Watch: Test incremental profit

RESEARCH INSIGHT

Margin contracted 520bps

Group EBITDA margin changed from 36.4 % (Q2 FY26) to 31.2 % (Q2 FY27). Margin contracted 520bps.

Watch: Watch materials and yield

RESEARCH INSIGHT

PAT barely improved

Group PAT changed from 55 ₹ crore (Q2 FY26) to 56 ₹ crore (Q2 FY27). PAT barely improved.

Watch: Reconcile cash

FULL PUBLISHED RESEARCH

Earnings and management commentary analysis

Quarter ended 30 September 2026 · Stance WATCH · original issuer/exchange sources. The investor question is whether newly commercializing HALS chemistry can restore growth without permanently diluting an established specialty-chemical margin structure. Consolidated revenue grew from ₹245 crore to ₹299 crore, but EBITDA improved only from ₹87 crore to ₹92 crore. At 31.2% group EBITDA margin versus 36.4% a year earlier, stronger top line does not yet prove attractive incremental returns. WATCH until new capacity generates reliable cash and a sustainable product-margin mix. [S1][S2]

Decision metricEarlier referenceLatest reference
Group quarterly revenue245 ₹ crore (Q2 FY26)299 ₹ crore (Q2 FY27)
Group quarterly EBITDA87 ₹ crore (Q2 FY26)92 ₹ crore (Q2 FY27)
Group EBITDA margin36.4 % (Q2 FY26)31.2 % (Q2 FY27)
Group PAT55 ₹ crore (Q2 FY26)56 ₹ crore (Q2 FY27)
Standalone quarterly sales211 ₹ crore (Q2 FY26)233 ₹ crore (Q2 FY27)
Standalone EBITDA90 ₹ crore (Q2 FY26)82 ₹ crore (Q2 FY27)
Consolidated H1 revenue488 ₹ crore (H1 FY26)568 ₹ crore (H1 FY27)
Consolidated H1 EBITDA187 ₹ crore (H1 FY26)188 ₹ crore (H1 FY27)

Key takeaways: Group quarterly revenue: Revenue rose 22%. Group quarterly EBITDA: EBITDA rose only 5%. Group EBITDA margin: Margin contracted 520bps. Group PAT: PAT barely improved. Standalone quarterly sales: Core sales improved. Standalone EBITDA: Mature site EBITDA weakened. All comparisons follow the issuer's specified dates, basis and units. The separate graphical Investment Briefing precedes the detailed main report.

Chapter 1 — Investment decision and valuation burden

The investor question is whether newly commercializing HALS chemistry can restore growth without permanently diluting an established specialty-chemical margin structure. Consolidated revenue grew from ₹245 crore to ₹299 crore, but EBITDA improved only from ₹87 crore to ₹92 crore. At 31.2% group EBITDA margin versus 36.4% a year earlier, stronger top line does not yet prove attractive incremental returns. WATCH until new capacity generates reliable cash and a sustainable product-margin mix. [S1][S2]

Issuer-specific financial checks and decisions

  • Group quarterly revenue: 299 ₹ crore (Q2 FY27) against 245 ₹ crore (Q2 FY26). Revenue rose 22%; Disaggregate subsidiary sales. [S2]
  • Group quarterly EBITDA: 92 ₹ crore (Q2 FY27) against 87 ₹ crore (Q2 FY26). EBITDA rose only 5%; Test incremental profit. [S2]
  • Group EBITDA margin: 31.2 % (Q2 FY27) against 36.4 % (Q2 FY26). Margin contracted 520bps; Watch materials and yield. [S2]

Monitoring interpretation. Revenue rose 22%. The practical next-quarter test is: disaggregate subsidiary sales. EBITDA rose only 5%. The practical next-quarter test is: test incremental profit. Margin contracted 520bps. The practical next-quarter test is: watch materials and yield. These observations help distinguish underlying operating economics from stated management ambitions; they do not establish an unreported entry price, dividend, free cash flow or earnings forecast.

Chapter 2 — Quarter and H1 financials and earnings quality

The Q2 standalone business reported ₹233 crore revenue versus ₹211 crore a year ago, but EBITDA declined from ₹90 crore to ₹82 crore; the subsidiary's contribution improves consolidated sales but cannot disguise core cost pressure. H1 consolidated revenue was ₹568 crore versus ₹488 crore, while EBITDA was nearly unchanged at ₹188 crore versus ₹187 crore. Product/raw-material costs increased substantially. Distinguish reported group PAT of approximately ₹56 crore from underlying EBITDA and operating-cash-flow conversion. [S1][S2]

Issuer-specific financial checks and decisions

  • Group EBITDA margin: 31.2 % (Q2 FY27) against 36.4 % (Q2 FY26). Margin contracted 520bps; Watch materials and yield. [S2]
  • Group PAT: 56 ₹ crore (Q2 FY27) against 55 ₹ crore (Q2 FY26). PAT barely improved; Reconcile cash. [S2]
  • Standalone quarterly sales: 233 ₹ crore (Q2 FY27) against 211 ₹ crore (Q2 FY26). Core sales improved; Review export realization. [S2]

Monitoring interpretation. Margin contracted 520bps. The practical next-quarter test is: watch materials and yield. PAT barely improved. The practical next-quarter test is: reconcile cash. Core sales improved. The practical next-quarter test is: review export realization. These observations help distinguish underlying operating economics from stated management ambitions; they do not establish an unreported entry price, dividend, free cash flow or earnings forecast.

Chapter 3 — Product, segment and channel economics

The core performance, pharmaceutical and FMCG intermediates are established products, whereas HALS output through Clean Fino Chem is still scaling. Management reported HALS approximately doubled in revenue on a year-over-year basis and reached roughly 22% of sales. The top four legacy products account for about 58% now versus about 85% in Q4 FY23. That diversifies sales sources but adds qualification and process-yield risks; sales share is not necessarily profit share. [S1][S2]

Issuer-specific financial checks and decisions

  • Standalone quarterly sales: 233 ₹ crore (Q2 FY27) against 211 ₹ crore (Q2 FY26). Core sales improved; Review export realization. [S2]
  • Standalone EBITDA: 82 ₹ crore (Q2 FY27) against 90 ₹ crore (Q2 FY26). Mature site EBITDA weakened; Watch input costs. [S2]
  • Consolidated H1 revenue: 568 ₹ crore (H1 FY27) against 488 ₹ crore (H1 FY26). Six-month growth about 16%; Review utilization. [S2]

Monitoring interpretation. Core sales improved. The practical next-quarter test is: review export realization. Mature site EBITDA weakened. The practical next-quarter test is: watch input costs. Six-month growth about 16%. The practical next-quarter test is: review utilization. These observations help distinguish underlying operating economics from stated management ambitions; they do not establish an unreported entry price, dividend, free cash flow or earnings forecast.

Chapter 4 — Execution promises, milestones and Q&A challenges

CFCL was described as adding roughly ₹48 crore of year-on-year sales and attaining positive PAT. The presentation said advanced HALS products underwent customer qualification with Geneus Chem AG, and additional performance chemicals were expected to commercialize in H2 FY27. These are milestones with verification dependencies rather than reported future revenue. Investors need approved customer grades, repeat volumes and yield data to distinguish product adoption from early orders. [S1][S2]

Issuer-specific financial checks and decisions

  • Consolidated H1 revenue: 568 ₹ crore (H1 FY27) against 488 ₹ crore (H1 FY26). Six-month growth about 16%; Review utilization. [S2]
  • Consolidated H1 EBITDA: 188 ₹ crore (H1 FY27) against 187 ₹ crore (H1 FY26). Six-month EBITDA flat; Test ramp economics. [S2]
  • Consolidated H1 PAT: 129 ₹ crore (H1 FY27) against 125 ₹ crore (H1 FY26). PAT rose about 3%; Check cost normalization. [S2]

Monitoring interpretation. Six-month growth about 16%. The practical next-quarter test is: review utilization. Six-month EBITDA flat. The practical next-quarter test is: test ramp economics. PAT rose about 3%. The practical next-quarter test is: check cost normalization. These observations help distinguish underlying operating economics from stated management ambitions; they do not establish an unreported entry price, dividend, free cash flow or earnings forecast.

Chapter 5 — Operating cash, capex, debt and payback

The company invested approximately ₹150 crore during H1 FY27 in CFCL. Consolidated inventories increased to ₹221 crore from ₹154 crore at March 2026, and receivables to ₹263 crore from ₹206 crore. These movements can absorb cash during a manufacturing ramp despite EBITDA profitability. The corporate presentation calls the firm zero debt; no fabricated period-specific free cash flow is derived without a reconciled cash-flow statement. [S1][S2]

Issuer-specific financial checks and decisions

  • Consolidated H1 PAT: 129 ₹ crore (H1 FY27) against 125 ₹ crore (H1 FY26). PAT rose about 3%; Check cost normalization. [S2]
  • Material spending: 128 ₹ crore (Q2 FY27) against 96 ₹ crore (Q2 FY26). Raw materials grew by one third; Monitor input contracts. [S2]
  • Consolidated inventories: 221 ₹ crore (Sep 2026) against 154 ₹ crore (Mar 2026). Inventory tied up more capital; Track turnover. [S2]

Monitoring interpretation. PAT rose about 3%. The practical next-quarter test is: check cost normalization. Raw materials grew by one third. The practical next-quarter test is: monitor input contracts. Inventory tied up more capital. The practical next-quarter test is: track turnover. These observations help distinguish underlying operating economics from stated management ambitions; they do not establish an unreported entry price, dividend, free cash flow or earnings forecast.

Chapter 6 — Bull, base and bear conditional scenarios

Bull: higher HALS utilization, product qualifications and normalized input costs restore margin from 31.2%. Base: revenue grows but subsidiary startup, process yields and raw material costs absorb much of the incremental profit. Bear: delayed acceptance, prolonged commodity inflation or rising inventory/receivables impair cash returns. Each scenario is falsifiable through customer repeat ordering, gross margin, and working-capital metrics rather than unsupported share-price targets. [S1][S2]

Issuer-specific financial checks and decisions

  • Group quarterly revenue: 299 ₹ crore (Q2 FY27) against 245 ₹ crore (Q2 FY26). Revenue rose 22%; Disaggregate subsidiary sales. [S2]
  • Group quarterly EBITDA: 92 ₹ crore (Q2 FY27) against 87 ₹ crore (Q2 FY26). EBITDA rose only 5%; Test incremental profit. [S2]
  • Group EBITDA margin: 31.2 % (Q2 FY27) against 36.4 % (Q2 FY26). Margin contracted 520bps; Watch materials and yield. [S2]

Monitoring interpretation. Revenue rose 22%. The practical next-quarter test is: disaggregate subsidiary sales. EBITDA rose only 5%. The practical next-quarter test is: test incremental profit. Margin contracted 520bps. The practical next-quarter test is: watch materials and yield. These observations help distinguish underlying operating economics from stated management ambitions; they do not establish an unreported entry price, dividend, free cash flow or earnings forecast.

Chapter 7 — Investor action plan and quarterly monitoring

WATCH and track core/CFCL margins separately. Observe standalone EBITDA ₹82 crore, group EBITDA ₹92 crore, the 22% HALS sales share, approximate H1 capex ₹150 crore, inventories ₹221 crore and receivables ₹263 crore. Reconcile growth from new products against their utilization, customer reorders and collected revenue. Demand at least two quarters of better conversion before capitalizing the next HALS grade launch at a premium valuation. [S1][S2]

Issuer-specific financial checks and decisions

  • Group EBITDA margin: 31.2 % (Q2 FY27) against 36.4 % (Q2 FY26). Margin contracted 520bps; Watch materials and yield. [S2]
  • Group PAT: 56 ₹ crore (Q2 FY27) against 55 ₹ crore (Q2 FY26). PAT barely improved; Reconcile cash. [S2]
  • Standalone quarterly sales: 233 ₹ crore (Q2 FY27) against 211 ₹ crore (Q2 FY26). Core sales improved; Review export realization. [S2]

Monitoring interpretation. Margin contracted 520bps. The practical next-quarter test is: watch materials and yield. PAT barely improved. The practical next-quarter test is: reconcile cash. Core sales improved. The practical next-quarter test is: review export realization. These observations help distinguish underlying operating economics from stated management ambitions; they do not establish an unreported entry price, dividend, free cash flow or earnings forecast.

Supporting issuer and exchange filings

[S1] — management discussion and analyst questions for the September 2026 quarter. [S2] — issuer financial and operating data.

Interpretive limits: Future product launches, order contracts, customer discussions, raw-material effects and project milestones are cited as management commentary where relevant, not realized future profits. Valuation figures, project payback, market prices, leverage and cash conversions are omitted where the saved issuer evidence is inadequate.

Additional company evidence

CHART 5

Standalone quarterly sales

Q2 FY26₹211 crore
Q2 FY27₹233 crore
CHART 6

Standalone EBITDA

Q2 FY26₹90 crore
Q2 FY27₹82 crore
CHART 7

Consolidated H1 revenue

H1 FY26₹488 crore
H1 FY27₹568 crore
CHART 8

Consolidated H1 EBITDA

H1 FY26₹187 crore
H1 FY27₹188 crore
SOURCE REFERENCES

Original disclosures and investor presentations

Original references are in the published manuscript below.

Related research and comparisons

Other published Q2 FY27 reports

This is dated research, not a live market quote. Scenarios and historical performance are not guarantees.